Jane E. Kiernan net worth and biography

Jane Kiernan Biography and Net Worth

Director of Axonics
Jane E. Kiernan has over 30 years of executive and management leadership in healthcare with both public and private companies. Kiernan joined the Axonics Board of Directors on April 8, 2019 and serves on the Audit Committee. Kiernan is a cofounder of K2 Biotechnology Ventures, an organization engaged in developing and commercializing university and medical center innovations in partnership with venture capital, healthcare corporations and philanthropic healthcare foundation partners. From 2010–2017, Kiernan served as the CEO of Salter Labs, a manufacturer of specialty medical devices with approximately 1,000 employees and $85 million in annual revenue. From 2006–2011, Kiernan served on the Board of Directors and as Chair of the Audit Committee of Nasdaq-listed American Medical Systems (AMS) prior to AMS being acquired by Endo Pharmaceuticals (NASDAQ: ENDP) for $2.9 billion. From 2001–2010, Kiernan held executive and general management positions with profit and loss responsibility for as much as $1.5 billion in revenue with both Baxter Healthcare Corporation and Allegiance Healthcare Corporation. As a community leader, Kiernan serves on the Board of Directors for Ryan Banks Academy and has served on the Board of Directors of the American Red Cross of Greater Chicago. In addition, she is a past President of the Healthcare Businesswomen’s Association, Chicago Chapter. Kiernan holds a B.S. degree in business from Southern Methodist University.

What is Jane E. Kiernan's net worth?

The estimated net worth of Jane E. Kiernan is at least $1.42 million as of April 1st, 2022. Ms. Kiernan owns 20,011 shares of Axonics stock worth more than $1,415,778 as of September 29th. This net worth estimate does not reflect any other investments that Ms. Kiernan may own. Learn More about Jane E. Kiernan's net worth.

How do I contact Jane E. Kiernan?

The corporate mailing address for Ms. Kiernan and other Axonics executives is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. Axonics can also be reached via phone at (866) 722-5738 and via email at [email protected] Learn More on Jane E. Kiernan's contact information.

Has Jane E. Kiernan been buying or selling shares of Axonics?

During the last ninety days, Jane E. Kiernan has sold $315,000.00 in shares of Axonics stock. Most recently, Jane E. Kiernan sold 5,250 shares of the business's stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $60.00, for a transaction totalling $315,000.00. Following the completion of the sale, the director now directly owns 14,761 shares of the company's stock, valued at $885,660. Learn More on Jane E. Kiernan's trading history.

Who are Axonics' active insiders?

Axonics' insider roster includes Juliet Bakker (Director), Raymond Cohen (CEO), Danny Dearen (Insider), Alfred Ford, Jr. (Insider), Jane Kiernan (Director), Robert Mcnamara (Director), Karen Noblett (Insider), Rinda Sama (COO), and John Woock (CMO). Learn More on Axonics' active insiders.

Are insiders buying or selling shares of Axonics?

During the last year, insiders at the sold shares 23 times. They sold a total of 429,581 shares worth more than $26,014,285.35. The most recent insider tranaction occured on September, 13th when insider Danny L Dearen sold 656 shares worth more than $49,593.60. Insiders at Axonics own 2.3 % of the company. Learn More about insider trades at Axonics.

Information on this page was last updated on 9/13/2022.

Jane E. Kiernan Insider Trading History at Axonics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/5/2022Sell5,250$60.00$315,000.0014,761View SEC Filing Icon  
4/1/2022Sell1,750$62.71$109,742.5020,011View SEC Filing Icon  
3/29/2022Sell5,250$60.50$317,625.00View SEC Filing Icon  
See Full Table

Jane E. Kiernan Buying and Selling Activity at Axonics

This chart shows Jane E Kiernan's buying and selling at Axonics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Axonics Company Overview

Axonics logo
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Read More

Today's Range

Now: $70.77
Low: $69.91
High: $71.50

50 Day Range

MA: $70.79
Low: $61.25
High: $78.12

2 Week Range

Now: $70.77
Low: $38.41
High: $79.92


397,064 shs

Average Volume

559,053 shs

Market Capitalization

$3.33 billion

P/E Ratio


Dividend Yield